How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

35,372 results for

Heart Failure Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER). (PubMed)

Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER). The health-related quality of life (HRQoL) is an important treatment goal that could serve as low-cost prognostication tool in resource poor settings. We sought to validate the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluate its use as a predictor of 3 months all-cause mortality among heart failure participants (...) in rural Uganda.The Mbarara Heart Failure Registry Cohort study observes heart failure patients during hospital stay and in the community in rural Uganda. Participants completed health failure evaluations and HRQoL questionnaires at enrollment, 1 and 3 months of follow-up. We used Cronbach's alpha coefficients to define internal consistency, intraclass correlation coefficients as a reliability coefficient, and Cox proportional hazard models to predict the risk of 3 months all-cause mortality.Among

Full Text available with Trip Pro

2018 BMC Cardiovascular Disorders

2. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer

incorporat- ing N-terminal pro-B-type natriuretic peptide levels: a European coLlabo- ration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart. 2014;100:115–25. 109. Flint KM, Allen LA, Pham M, et al. B-type natriuretic peptide predicts 30- day readmission for heart failure but not readmission for other causes. J Am Heart Assoc. 2014;3:e000806. 110. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized (...) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer CLINICAL STATEMENTS AND GUIDELINES Circulation. 2017;136:e137–e161. DOI: 10.1161/CIR.0000000000000509 August 8, 2017 e137 WRITING GROUP MEMBERS* Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair Mariell Jessup, MD, FACC, FAHA, Vice Chair

2017 American Heart Association

3. Drugs That May Cause or Exacerbate Heart Failure

Drugs That May Cause or Exacerbate Heart Failure Drugs That May Cause or Exacerbate Heart Failure | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share (...) on Jump to Free Access article Drugs That May Cause or Exacerbate Heart Failure A Scientific Statement From the American Heart Association , PharmD, MSPH, FAHA, Chair , PharmD , MD, MSc , MD , MD, MSCE , MB ChB, FAHA , PharmD , and PhD, ACNP-BC, FAHA MD, FAHA, Co-ChairOn behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular

Full Text available with Trip Pro

2016 American Heart Association

4. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinic

directly or indirectly can cause angioedema. 32,33 An ARNI should not be administered within 36 hours of switching from or to an ACE inhibitor. Recommendations for Renin-Angiotensin System Inhibition With ACe Inhibitor or ARb or ARNI (Continued) CoR Loe Recommendations (Continued ) Downloaded from http://ahajournals.org by on March 27, 2019CLINICAL St AteMeNtS ANd GuIdeLINeS Heart Failure Focused Update on Pharmacological Therapy Circulation. 2016;134:e282-e293. DOI: 10.1161/CIR.0000000000000435 (...) 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinic ACC/AHA/HFSA FoCuSed upd Ate September 27, 2016 Circulation. 2016;134:e282–e293. DOI: 10.1161/CIR.0000000000000435 e282 Developed in Collaboration With the American College of Chest Physi- cians and International Society for Heart and Lung

Full Text available with Trip Pro

2016 American Heart Association

5. Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure (PubMed)

Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-rheumatic medications frequently used in the treatment of connective tissue disorders. We present the case of a 45-year-old woman with CQ-induced cardiomyopathy leading to severe heart failure. Electrocardiographic abnormalities included bifascicular block, while structural disease consisted of severe biventricular and biatrial hypertrophy. Appropriate diagnosis via (...) for some heterogeneity of disease presentation.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Full Text available with Trip Pro

2018 ESC heart failure

6. Chronic heart failure in adults: diagnosis and management

causes for symptoms of heart failure in people with NT- proBNP levels below 400 ng/litre. If there is still concern that the symptoms might be related to heart failure, discuss with a physician with subspeciality training in heart failure. [2018] [2018] 1.2.7 Be aware that: obesity, African or African–Caribbean family origin, or treatment with diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin II receptor blockers (ARBs) or mineralocorticoid receptor antagonists (...) (MRAs) can reduce levels of serum natriuretic peptides high levels of serum natriuretic peptides can have causes other than heart failure (for example, age over 70 years, left ventricular hypertrophy, ischaemia, tachycardia, right ventricular overload, hypoxaemia [including pulmonary embolism], renal dysfunction [eGFR less than 60 ml/minute/1.73 m 2 ], sepsis, chronic obstructive pulmonary disease, diabetes, or cirrhosis of the liver). [2010, amended 2018] [2010, amended 2018] 1.2.8 Perform

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches. (PubMed)

Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches. Several attempts have been made at developing models to predict 30-day readmissions in patients with heart failure, but none have sufficient discriminatory capacity for clinical use. Machine-learning (ML) algorithms represent a novel approach and may have potential advantages over traditional statistical modeling.To develop models using a ML (...) approach to predict all-cause readmissions 30 days after discharge from a heart failure hospitalization and to compare ML model performance with models developed using "conventional" statistically based methods.Models were developed using ML algorithms, specifically, a tree-augmented naive Bayesian network, a random forest algorithm, and a gradient-boosted model and compared with traditional statistical methods using 2 independently derived logistic regression models (a de novo model and an a priori

Full Text available with Trip Pro

2017 JAMA cardiology

8. Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation (PubMed)

Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation Quantification of systolic function in patients with atrial fibrillation (AF) is challenging. A novel approach, based on RR interval correction, to counteract the varying heart cycle lengths in AF has recently been proposed. Whether this method is superior in patients with systolic heart failure (HFrEF) with AF remains unknown (...) adjustment (age, sex, mean heart rate, mean arterial blood pressure, left atrial volume index, and E/e') (hazard ratio 1.17, 95% confidence interval 1.05-1.31, P = 0.005 per %/s^(1/2) decrease).Decreasing {GLSc = GLS/[RR^(1/2)]}, but not uncorrected GLS nor left ventricular ejection fraction, was significantly associated with increased risk of all-cause mortality in HFrEF patients with AF and remained an independent predictor after multivariable adjustment.© 2017 The Authors. ESC Heart Failure published

Full Text available with Trip Pro

2017 ESC heart failure

9. Exercise-based cardiac rehabilitation for adults with heart failure. (PubMed)

Exercise-based cardiac rehabilitation for adults with heart failure. Chronic heart failure (HF) is a growing global health challenge. People with HF experience substantial burden that includes low exercise tolerance, poor health-related quality of life (HRQoL), increased risk of mortality and hospital admission, and high healthcare costs. The previous (2014) Cochrane systematic review reported that exercise-based cardiac rehabilitation (CR) compared to no exercise control shows improvement (...) , number needed to treat: 25). After CR, a clinically important improvement in short-term disease-specific health-related quality of life may be evident (Minnesota Living With Heart Failure questionnaire - 17 trials, 18 comparisons (1995 participants): mean difference (MD) -7.11 points, 95% CI -10.49 to -3.73; low-quality evidence). Pooling across all studies, regardless of the HRQoL measure used, shows there may be clinically important improvement with exercise (26 trials, 29 comparisons (3833

2019 Cochrane

10. Disease management interventions for heart failure. (PubMed)

Disease management interventions for heart failure. Despite advances in treatment, the increasing and ageing population makes heart failure an important cause of morbidity and death worldwide. It is associated with high healthcare costs, partly driven by frequent hospital readmissions. Disease management interventions may help to manage people with heart failure in a more proactive, preventative way than drug therapy alone. This is the second update of a review published in 2005 and updated (...) , comparing disease management interventions to usual care for adults who had been admitted to hospital at least once with a diagnosis of heart failure. There were three main types of intervention: case management; clinic-based interventions; multidisciplinary interventions.We used standard methodological procedures expected by Cochrane. Outcomes of interest were mortality due to heart failure, mortality due to any cause, hospital readmission for heart failure, hospital readmission for any cause, adverse

2019 Cochrane

11. Chronic congestive heart failure

; a thorough history and physical examination should be obtained to identify cardiac and non-cardiac disorders or behaviours that might cause congestive heart failure or accelerate progression. The single most useful diagnostic test in the evaluation of patients is the comprehensive 2-dimensional echocardiogram coupled with Doppler flow studies. Measurement of B-type natriuretic peptide can be useful in the evaluation of patients at initial presentation. Interventions that have a proven beneficial impact (...) Chronic congestive heart failure Chronic congestive heart failure - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic congestive heart failure Last reviewed: February 2019 Last updated: January 2019 Summary A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is a major and growing public health

2019 BMJ Best Practice

12. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

2018 Circulation. 2018;137:e578–e622 You are viewing the most recent version of this article. Previous versions: Abstract Background and Purpose: The diverse causes of right-sided heart failure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading resulting from pulmonic stenosis or pulmonary (...) Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January

Full Text available with Trip Pro

2018 American Heart Association

13. Non-sarcomeric causes of heart failure: a Sydney Heart Bank perspective (PubMed)

Non-sarcomeric causes of heart failure: a Sydney Heart Bank perspective 30022358 2018 11 14 1867-2450 10 4 2018 Aug Biophysical reviews Biophys Rev Non-sarcomeric causes of heart failure: a Sydney Heart Bank perspective. 949-954 10.1007/s12551-018-0441-4 Dos Remedios C G CG Sydney Heart Bank, Bosch Institute, Anderson Stuart Building (F13), University of Sydney, Sydney, 2006, Australia. cris.dosremedios@sydney.edu.au. Li A A Sydney Heart Bank, Bosch Institute, Anderson Stuart Building (F13 (...) ), University of Sydney, Sydney, 2006, Australia. Lal S S Sydney Heart Bank, Bosch Institute, Anderson Stuart Building (F13), University of Sydney, Sydney, 2006, Australia. eng Journal Article Review 2018 07 18 Germany Biophys Rev 101498573 1867-2450 2018 07 02 2018 07 03 2018 7 20 6 0 2018 7 20 6 1 2018 7 20 6 0 ppublish 30022358 10.1007/s12551-018-0441-4 10.1007/s12551-018-0441-4 PMC6082304 J Cell Biol. 2010 Dec 13;191(6):1159-72 21149568 J Mol Cell Cardiol. 2002 Apr;34(4):413-26 11991731 Electrophoresis

Full Text available with Trip Pro

2018 Biophysical reviews

14. Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. (PubMed)

Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. Elevated serum uric acid (SUA) is associated with poor prognosis in patients with cardiovascular disease, yet it is still not decided whether the role of SUA is causal or only reflects an underlying disease. The purpose of the study was to investigate if SUA was an independent predictor of 5-year all-cause mortality in a propensity score matched cohort of chronic heart failure (HF (...) ) outpatients. Furthermore, to assess whether gender or renal function modified the effect of SUA.Patients (n = 4684) from the Norwegian Heart Failure Registry with baseline SUA were included in the study. Individuals in the highest gender-specific SUA quartile were propensity score matched 1:1 with patients in the lowest three SUA quartiles. The propensity score matching procedure created 928 pairs of patients (73.4% males, mean age 71.4 ± 11.5 years) with comparable baseline characteristics. Kaplan Meier

Full Text available with Trip Pro

2019 BMC Cardiovascular Disorders

15. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily

Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily Circulating 25-hydroxyvitamin D (25OHD) levels <75 nmol/L are associated with a nonlinear increase in mortality risk. Such 25OHD levels are common in heart failure (HF). We therefore examined whether oral vitamin D supplementation reduces mortality in patients with advanced HF.Four hundred HF patients with 25OHD levels <75 nmol/L were randomized to receive 4000 IU (...) vitamin D daily or matching placebo for 3 years. Primary endpoint was all-cause mortality. Key secondary outcome measures included hospitalization, resuscitation, mechanical circulatory support (MCS) implant, high urgent listing for heart transplantation, heart transplantation, and hypercalcaemia. Initial 25OHD levels were on average <40 nmol/L, remained around 40 nmol/L in patients assigned to placebo and plateaued around 100 nmol/L in patients assigned to vitamin D. Mortality was not different

Full Text available with Trip Pro

2017 EvidenceUpdates

16. Atrial fibrillation among adults with heart failure in sub-Saharan Africa - prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. (PubMed)

Atrial fibrillation among adults with heart failure in sub-Saharan Africa - prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. Heart failure (HF) remains a major non-communicable disease in sub-Saharan Africa (SSA) associated with high rates of readmission, mortality and loss of economic productivity as it affects mostly young and economically active adults. Atrial fibrillation (AFib) is a major determinant of mortality among patients with HF in SSA (...) . Meanwhile, the use of anti-arrhythmic medications in the region remains unacceptably low. This review aims to evaluate the prevalence and incidence of AFib in adult patients with HF in SSA, and the all-cause mortality rate among patients with HF and AFib.The Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015 statement was used to prepare this protocol. All eligible studies from database inception to December, 31 2018 in MEDLINE, Embase, Google Scholar, Web of science

Full Text available with Trip Pro

2019 BMJ open

17. Impact of Hospice and Palliative Care Service Utilization on All-Cause 30-Day Readmission Rate for Older Adults Hospitalized With Heart Failure. (PubMed)

Impact of Hospice and Palliative Care Service Utilization on All-Cause 30-Day Readmission Rate for Older Adults Hospitalized With Heart Failure. Acute decompensated heart failure (HF) is the leading cause for hospital readmission. Large-scale sustainable interventions to reduce readmission rate have not been fully explored or proven effective.We studied the impact of hospice and palliative care service utilization on 30-day all-cause hospital readmissions for patients with HF.Data were (...) of older US Veterans, utilization of hospice and palliative care services was associated with a higher 30-day all-cause readmission rate among hospitalized patients with HF. Further prospective studies should be conducted to confirm results and test generalizability outside the Veterans Affairs system of care.

2019 American Journal of Hospice and Palliative Medicine

18. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. (PubMed)

Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Guidelines recommend angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) for treatment of heart failure with reduced ejection fraction (HFrEF), but these medications are underprescribed in clinical practice. We reviewed the records of HF patients receiving a first visit in a tertiary outpatient clinic from January 1st (...) with an almost twofold increased risk of all-cause mortality (HR 1.97, 95%CI 1.39-2.80). ACEi/ARB underuse in HFrEF is a standing issue with dramatic prognostic consequences. Efforts are needed to eliminate perceived contraindications to these drugs and ensure their implementation in real-life cardiology.

2019 Internal and emergency medicine

19. Delays in Anti-Hyperglycemic Therapy Initiation and Intensification are Associated with Cardiovascular Events, Heart Failure Hospitalizations, and All-Cause Mortality. (PubMed)

Delays in Anti-Hyperglycemic Therapy Initiation and Intensification are Associated with Cardiovascular Events, Heart Failure Hospitalizations, and All-Cause Mortality. To assess the impact of delays in treatment intensification (TI) on cardiovascular events, heart failure, and all-cause mortality at typical stages of anti-hyperglycemic therapy.Using electronic health record data, we created three TI cohorts of diabetes patients who: 1) initiated metformin (MET) as their first anti-hyperglycemic (...) therapy; 2) added a sulfonylurea (SU) to MET; and 3) initiated insulin (INS) while using MET or SU alone or in combination. Our primary exposure variables were pre-TI A1C (hemoglobin A1C preceding the cohort therapy), and time to intensification (time between pre-TI A1C >7% and cohort index date). We used Cox regression models to analyze the associated risk of the cardiovascular events, heart failure hospitalizations, and all-cause mortality.In the MET cohort, each additional percentage point of pre

2019 obesity & metabolism

20. Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. (PubMed)

Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Atrial fibrillation (AF) is sustained by reentrant mechanisms that depend, in part, on atrial structural remodeling. Increased Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity occurs in persistent AF. A general consensus has been that electrophysiological actions of CaMKII must be the contributing factor, but electrical remodeling in AF differs (...) considerably with electrophysiological effects of CaMKII. CaMKII has been associated with structural remodeling in several tissues, but not the cardiac atria. The role of CaMKII in sustaining AF remains undefined.The purpose of this study was to assess the effects of CaMKII on AF-related structural remodeling.We evaluated the objective in a porcine AF-heart failure model using atrial gene transfer of the CaMKII inhibitory peptide CaMKIIn. We used conventional methods including in vivo electrophysiological

2019 Heart Rhythm

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>